neuronal PAS domain protein 3Genealiases: MOP6 · PASD6 · bHLHe12
Q-omics provides the consensus-scored NPAS3 profile across patient tissues and cancer cell-line models. NPAS3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in OV. Among the 18 cancer types available for tumor–normal comparison, NPAS3 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, NPAS3 RNA expression shows 15,477 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight OV, KIRC, and TGCT as cancer lineages where NPAS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPAS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPAS3 survival associations across molecular data types. NPAS3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (10) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPAS3 RNA expression–survival associations across cancer types. High NPAS3 expression shows favorable associations in OV, BRCA, UVM, THCA, KIRP and PAAD. The OV Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify OV as the clearest survival context for NPAS3 RNA expression.
This table summarizes NPAS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for NPAS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPAS3 shows lower tumor expression in KIRC, COAD, BRCA, READ and BLCA and higher tumor expression in UCEC. The KIRC box plot shows higher NPAS3 RNA expression in normal versus tumor tissue (log2 FC = −0.500, t-test p < 0.001).
This table shows molecular features associated with NPAS3 in patient tissues and cancer cell lines. In patient samples, NPAS3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NPAS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
